56 assets in Mesothelioma

Therapeutic assets addressing Mesothelioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Mesothelioma	National Cancer Institute (NCI)	P2	BB (65)
Fludarabine Mesothelioma	National Cancer Institute (NCI)	P2	B (60)
Nivolumab Mesothelioma	Orion Corporation, Orion Pharma	P2	B (60)
Pembrolizumab Mesothelioma	Genmab	P2	B (58)
Fludeoxyglucose Mesothelioma	National Cancer Institute (NCI)	P2	B (57)
Irinotecan Mesothelioma	Genmab	P1/2	CCC (55)
Tislelizumab Mesothelioma	HiFiBiO Therapeutics	P2	CCC (55)
FAPI74 Mesothelioma	National Cancer Institute (NCI)	P2	CCC (53)
TIL Mesothelioma	Udai Kammula	P2	CCC (51)
Atezolizumab Mesothelioma	KaliVir Immunotherapeutics	P1/2	CCC (50)
Osimertinib Mesothelioma	Ikena Oncology	P1/2	CCC (48)
Spartalizumab Mesothelioma	SOLTI Breast Cancer Research Group	P2	CC (46)
[203pb]pb-psv359 Mesothelioma	Perspective Therapeutics	P1/2	CC (45)
[212pb]pb-psv359 Mesothelioma	Perspective Therapeutics	P1/2	CC (45)
a2b543 Mesothelioma	A2 Biotherapeutics Inc.	P1/2	CC (45)
a2b694 Mesothelioma	A2 Biotherapeutics Inc.	P1/2	CC (45)
Ipilimumab Mesothelioma	Orion Corporation, Orion Pharma	P1/2	CC (45)
Odm-212 Mesothelioma	Orion Corporation, Orion Pharma	P1/2	CC (45)
Sotorasib Mesothelioma	Orion Corporation, Orion Pharma	P1/2	CC (45)
Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- Mesothelioma	Ikena Oncology	P1	CC (43)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Mesothelioma	VM Oncology, LLC	P1/2	CC (43)
Carboplatin Mesothelioma	Genmab	P1/2	CC (43)
Dexasone Mesothelioma	Takeda	P1/2	CC (43)
Gavo-Cel Mesothelioma	TCR2 Therapeutics	P1/2	CC (43)
Icasp9M28Z T Cell Infusions Mesothelioma	Memorial Sloan Kettering Cancer Center	P1/2	CC (43)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide Mesothelioma	Genmab	P1/2	CC (43)
ngm707 Mesothelioma	NGM Biopharmaceuticals, Inc	P1/2	CC (43)
Rso-021 Mesothelioma	RS Oncology LLC	P1/2	CC (43)
Tak-500 Mesothelioma	Takeda	P1/2	CC (43)
tc-510 Mesothelioma	TCR2 Therapeutics	P1/2	CC (43)
Tocilizumab Mesothelioma	Takeda	P1/2	CC (43)
vt3989 Mesothelioma	Vivace Therapeutics, Inc	P1/2	CC (43)
Arog4-01 Mesothelioma	Aromics Therapeutics	P1	CC (41)
bgc515 Mesothelioma	BridGene Biosciences Inc.	P1	CC (41)
ide892 Mesothelioma	IDEAYA Biosciences	P1	CC (41)
MAT2A-IN-9 Mesothelioma	IDEAYA Biosciences	P1	CC (41)
nxp900 Mesothelioma	Nuvectis Pharma, Inc.	P1	CC (41)
Tnhyp217 Car T Cells Mesothelioma	National Cancer Institute (NCI)	P1	CC (41)
vet3-tgi Mesothelioma	KaliVir Immunotherapeutics	P1	CC (41)
ag-01 compound Mesothelioma	A&G Pharmaceutical Inc.	P1	C (39)
Apg-5918 Mesothelioma	Ascentage Pharma Group Inc.	P1	C (39)
Durvalumab Mesothelioma	NeoTX Therapeutics Ltd.	P1	C (39)
Emunkitug Mesothelioma	HiFiBiO Therapeutics	P1	C (39)
iag933 Mesothelioma	Novartis Pharmaceuticals	P1	C (39)
kfa115 Mesothelioma	Novartis Pharmaceuticals	P1	C (39)
Mrtx1719 Mesothelioma	Bristol-Myers Squibb	P1	C (39)
mt-8421 Mesothelioma	Molecular Templates, Inc.	P1	C (39)
Naptumomab Estafenatox Mesothelioma	NeoTX Therapeutics Ltd.	P1	C (39)
ngm438 Mesothelioma	NGM Biopharmaceuticals, Inc	P1	C (39)
ngm831 Mesothelioma	NGM Biopharmaceuticals, Inc	P1	C (39)

Showing 1 to 50 of 56 assets

PreviousPage 1 of 2Next